Notify me when Northpond Ventures III, LP files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| KYTX | Kyverna Therapeutics, Inc. | Common Stock, par value $0.00001 per share | 6.1% | $28,531,978 | 3,466,826 | Michael P. Rubin | 31 Dec 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|